← Feed

u/microcapreturns

3 theses · first seen Oct 20, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$GANXr/pennystocksGeneral Discussionbullish
u/microcapreturns · 231d ago2 prior · awaiting results

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s?

Gain Therapeutics' lead drug GT-02287 has demonstrated statistically significant UPDRS improvement in Parkinson's patients and is expected to present neuron repair and DDC biomarker data at the AD/PD conference on 3/18/26, potentially validating the first disease-modifying drug to reverse Parkinson's. With a market cap around $125M and cash runway through end of year, the company is likely a takeover target for big pharma partners valuing Parkinson's assets at billions.

Now $1.19as of Oct 21, 4:00 PM ET
original post →
$GANXr/pennystocksStock Infobullish
u/microcapreturns · 321d ago2 prior · awaiting results

Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days

Phase 1b trial data shows GT-02287 achieved statistically significant UPDRS score improvement in Parkinson's patients within 90 days, unprecedented for a short trial duration. With a small market cap relative to Parkinson's market size and upcoming full data readout expected to confirm the effect across all 16 patients, the stock has significant upside potential if the drug represents a true disease-modifying breakthrough.

Now $1.19as of Oct 21, 4:00 PM ET
original post →
$GANXr/pennystocksGeneral Discussionbullish
u/microcapreturns · 331d ago2 prior · awaiting results

Gain Therapeutics($GANX) has returned Smell to Parkinson's patients in 2025 and has major catalysts before year end

Gain Therapeutics' GT-02287 has demonstrated disease-modifying effects in Parkinson's trials, including restoration of smell and UPDRS improvements in just 90 days. Multiple catalysts before year-end (additional patient data, biomarker results, FDA IND submission) combined with high trial demand suggest significant upside potential and a likely acquisition by big pharma.

Now $1.19as of Oct 21, 4:00 PM ET
original post →

End of results.